Kiora Pharmaceuticals, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.515 USD | +2.98% | +5.32% | -1.42% |
05-10 | Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M | MT |
03-25 | Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.42% | 13.13M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- KPRX Stock
- News Kiora Pharmaceuticals, Inc.
- Kiora Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt